FDA Inspection 922741 — Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany
The FDA completed an inspection of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on April 24, 2015 in Whippany, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- April 24, 2015
- Fiscal Year
- 2015
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Whippany, NJ (United States)